ENTRADA THERAPEUTICS, INC. Variable Lease, Cost
ENTRADA THERAPEUTICS, INC. (TRDA) reported Variable Lease, Cost of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-26
- ENTRADA THERAPEUTICS, INC. variable lease, cost for the quarter ending 2023-12-31 was $0.00.
- ENTRADA THERAPEUTICS, INC. variable lease, cost for the quarter ending 2023-09-30 was $0.00.
- ENTRADA THERAPEUTICS, INC. variable lease, cost for the quarter ending 2023-06-30 was $0.00.
- ENTRADA THERAPEUTICS, INC. variable lease, cost for the quarter ending 2023-03-31 was $0.00.
- ENTRADA THERAPEUTICS, INC. variable lease, cost for fiscal 2025 was $0.00.
- ENTRADA THERAPEUTICS, INC. variable lease, cost for fiscal 2024 was $0.00.
- ENTRADA THERAPEUTICS, INC. variable lease, cost for fiscal 2023 was $0.00.
- ENTRADA THERAPEUTICS, INC. variable lease, cost for fiscal 2022 was $0.00.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $0.00 10-K · filed 2024-03-13 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2023-08-08 | $0.00 derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-05-10 | $0.00 derived: sum of 3 quarters · filed 2023-05-10 | $0.00 derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 10-K · filed 2023-03-06 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |